Navigation Links
Abbott Announces Earnings Guidance for 2009
Date:1/12/2009

ABBOTT PARK, Ill., Jan. 12 /PRNewswire-FirstCall/ -- Abbott today is announcing its full-year earnings-per-share guidance for 2009 and confirming its previously issued 2008 earnings-per-share guidance of $3.31 to $3.33, excluding specified items. For 2009, the company expects earnings per share of $3.65 to $3.70 under Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. The midpoint of this 2009 guidance reflects double-digit growth over the midpoint of 2008 earnings-per-share guidance.

Abbott's 2009 outlook includes the acquisition of Advanced Medical Optics (AMO) as announced today (see separate news release). Abbott expects the AMO transaction to be neutral to ongoing earnings per share in 2009 and accretive in 2010, both before one-time transaction-related costs, which will be provided at a later date.

Further details regarding Abbott's earnings-per-share guidance for 2009 will be provided on the company's fourth-quarter 2008 earnings conference call scheduled for Jan. 21, 2009. Including net specified items, Abbott forecasts earnings per share for the full-year 2008 under GAAP of $3.04 to $3.06. Abbott forecasts net specified items for the full-year 2008 of $0.27 per share, primarily associated with previously announced cost reduction initiatives, acquired in-process R&D, and litigation settlements. These items were partially offset primarily by previously announced one-time gains from the sale of Abbott's spine business, conclusion of the TAP joint venture, and favorable tax settlements.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 co
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
2. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
3. Abbotts XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
4. Abbott Hosts Conference Call for Third-Quarter Earnings
5. Abbott to Present at UBS Best of Americas Investment Conference
6. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
7. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
8. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
9. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
10. Abbott Invests Additional $20M in Isis Subsidiary Ibis Biosciences
11. Abbott to Present at Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2014)... BELLINGHAM, Washington, USA (PRWEB) November 14, 2014 ... enter the SPIE Startup Challenge 2015 , an ... team of business development experts and venture capitalists. The ... at the Moscone Center in San Francisco, running ... society for optics and photonics . , Cash prizes, ...
(Date:11/15/2014)... 14, 2014 Research ... addition of the  "Protein Characterization and Identification ... & by End Users - Global Forecast ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The global protein characterization ... million in 2014, and is expected to ...
(Date:11/12/2014)... November 12, 2014 The “Pen Needles ... 10mm, and 12mm), Therapy (Insulin, Growth Hormones, Glucagon-like peptide) ... & Global Forecast to 2019”analyzes and studies the major ... 101 market data tables and 51 figures spread through ... by Type (Standard and Safety), by Needle Length (4mm, ...
(Date:11/12/2014)... and ANNAPOLIS JUNCTION, MD (PRWEB) November 11, 2014 ... , Brian Meshkin, spoke at the 8th Annual ... in Pain Management . The Annual Pain and Migraine ... of pain research and emerging therapeutic methods. The event ... communities to learn about the cutting-edge advances in various ...
Breaking Biology Technology:New Photonics Entrepreneurs Need to Apply Now for SPIE Startup Challenge 2015 2New Photonics Entrepreneurs Need to Apply Now for SPIE Startup Challenge 2015 3Global Protein Characterization and Identification (Chromatography, Electrophoresis, Mass Spectroscopy) Market - Forecast to 2019 2Global Protein Characterization and Identification (Chromatography, Electrophoresis, Mass Spectroscopy) Market - Forecast to 2019 3Pen Needles Market worth $2,105 Million by 2019 - New Report by MarketsandMarkets 2Pen Needles Market worth $2,105 Million by 2019 - New Report by MarketsandMarkets 3Pen Needles Market worth $2,105 Million by 2019 - New Report by MarketsandMarkets 4President of Proove Biosciences, Brian Meshkin, Speaks at the 8th Annual Pain Therapeutics Summit 2President of Proove Biosciences, Brian Meshkin, Speaks at the 8th Annual Pain Therapeutics Summit 3
... Oncology Adjuvant Trial 9735 at 2007 San, ... Improved Overall Survival Versus ... Results presented at the,30th annual San Antonio ... early stage breast cancer who have had surgery, ...
... FDA-defined Valvulopathy Permitted to Enroll in 2nd and ... Screening Requirement Eliminated, SAN DIEGO, Dec. 13 ... announced the initiation of patient screening in,the second ... efficacy and,safety of its lead drug candidate, lorcaserin ...
... SAN DIEGO, Dec. 13 BioMed Realty Trust, Inc.,(NYSE: ... I. Gilchrist to its,board of directors, increasing the board ... in the real estate industry, with a breadth of,ability ... large-scale commercial real estate projects. We believe that,Rick,s contributions ...
Cached Biology Technology:Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 2Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 3Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 4Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 6BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 3
(Date:11/11/2014)... Inc., a Chicago -based digital forensics ... of Yaniv Schiff from Senior Computer Forensics ... role as Director, he will lead company efforts to ... provide leadership within the company,s digital forensics practice area.  ... Schiff joined Forensicon in 2006 and has ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
(Date:11/7/2014)... CORAL SPRINGS, Florida , November 6, 2014 ... improved secure authentication for better mobile security revolutionizing online transactions. ... NXTD ), Alibaba Holdings Ltd. (NYSE: BABA ), ... MSFT ), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: NXTD and NXTDW), a biometric authentication ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... Scientists at Stanford University have developed a new laser ... unharmed. The new, non-invasive treatment is described in a ... the Proceedings of the National Academy of Sciences (PNAS). ... how to cure cancer without harming normal body tissue," ...
... from sensory neurons using a code more complicated than ... National Autonomous University of Mexico and Cold Spring Harbor ... when it touches the skin, scientists found that changes ... sensory signal is interpreted. , Howard Hughes Medical Institute ...
... looking deep under water for clues on how to ... Some of the stresses inherent with travel and life ... example - are not easily remedied with traditional plant ... Distinguished Professor of Botany, and Dr.Amy Grunden, assistant professor ...
Cached Biology News:Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 2Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 3Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 4Cracking the perception code 2Cracking the perception code 3NC State researchers redesign life for Mars and beyond 2
FITC~Bovine Serum Albumin...
Bovine Serum Albumin Heat Shock Diagnostic Grade Powder...
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: